4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide and leptin

4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide has been researched along with leptin in 2 studies

Compound Research Comparison

Studies (4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide)	Trials (4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide)	Recent Studies (post-2010) (4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide)	Studies (leptin)	Trials (leptin)	Recent Studies (post-2010) (leptin)
62	0	14	25,940	1,628	11,468

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Doi, M; Kano, S	1
Habu, S; Kusunoki, M; Miyata, T; Mori, Y; Morishita, M; Nakamura, A; Nakamura, T; Nakaya, Y; Sato, D; Tsutsumi, K; Yonemoto, T	1

Other Studies

2 other study(ies) available for 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide and leptin

Article	Year
NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats. Metabolism: clinical and experimental, 2006, Volume: 55, Issue:2 Topics: Adipose Tissue, Brown; Animals; Benzamides; Blood Glucose; Body Weight; Carrier Proteins; Eating; Fatty Acid Transport Proteins; Fatty Acid-Binding Proteins; Female; Gene Expression; Hypolipidemic Agents; Insulin; Ion Channels; Leptin; Mitochondrial Proteins; Muscle, Skeletal; Myocardium; Obesity; Organophosphorus Compounds; Ovariectomy; Oxygen Consumption; Proton-Translocating ATPases; Random Allocation; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Uncoupling Protein 3	2006
Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886. European journal of pharmacology, 2011, Oct-15, Volume: 668, Issue:3 Topics: Abdominal Fat; Adiponectin; Animals; Benzamides; Blood Glucose; Body Weight; Drug Combinations; Eating; Enzyme Activation; Hypoglycemic Agents; Insulin; Leptin; Lipids; Lipoprotein Lipase; Male; Organophosphorus Compounds; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazolidinediones	2011

Article

Year

NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats.

Metabolism: clinical and experimental, 2006, Volume: 55, Issue:2

Topics: Adipose Tissue, Brown; Animals; Benzamides; Blood Glucose; Body Weight; Carrier Proteins; Eating; Fatty Acid Transport Proteins; Fatty Acid-Binding Proteins; Female; Gene Expression; Hypolipidemic Agents; Insulin; Ion Channels; Leptin; Mitochondrial Proteins; Muscle, Skeletal; Myocardium; Obesity; Organophosphorus Compounds; Ovariectomy; Oxygen Consumption; Proton-Translocating ATPases; Random Allocation; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Uncoupling Protein 3

2006

Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886.

European journal of pharmacology, 2011, Oct-15, Volume: 668, Issue:3

Topics: Abdominal Fat; Adiponectin; Animals; Benzamides; Blood Glucose; Body Weight; Drug Combinations; Eating; Enzyme Activation; Hypoglycemic Agents; Insulin; Leptin; Lipids; Lipoprotein Lipase; Male; Organophosphorus Compounds; Pioglitazone; Rats; Rats, Sprague-Dawley; Thiazolidinediones

2011